Sandoz Group (OTCMKTS:SDZNY) Hits New 52-Week High – Still a Buy?

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY)’s stock price reached a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $95.00 and last traded at $94.50, with a volume of 3,631 shares. The stock had previously closed at $93.56.

Analyst Ratings Changes

Separately, Erste Group Bank raised Sandoz Group to a “strong-buy” rating in a report on Thursday, August 27th. Four analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Strong Buy”.

Sandoz Group Price Performance

The business has a 50-day simple moving average of $86.45 and a two-hundred day simple moving average of $84.56.

Sandoz Group Company Profile

Sandoz Group AG is a Switzerland-based pharmaceutical company focused on generic and biosimilar medicines. Its portfolio includes prescription medicines across therapeutic areas such as anti-infectives, immunology, oncology, ophthalmology, respiratory care and cardiovascular treatments. The company also supplies complex generics, including injectable, inhaled and other specialty formulations.

Sandoz serves patients and healthcare providers through a broad international commercial and manufacturing network, with operations and products spanning Europe, North America, Asia and other global markets.